In January 2026, Hong Kong pharmaceutical companies launched intensive acquisition and authorization transactions!
The above merger and acquisition transactions reflect the trend of industry resources being concentrated in hard technology and commercialization capabilities. It is worth noting that, in addition to mergers and acquisitions, several Hong Kong listed pharmaceutical companies have authorized overseas equity of their core assets to multinational pharmaceutical companies since 2026.
01.21,2026 views